申请人:STARPHARMA LIMITED
公开号:US20030129158A1
公开(公告)日:2003-07-10
To inhibit, prophylactically or therapeutically, a bacterial, yeast, fungal, or parasitic agent in a patient, an effective amount of a dendrimer is administered to the patient, which dendrimer has a plurality of terminal groups, at least one of which has an anionic- or cationic-moiety covalently bonded or linked thereto. The anionic-containing moiety is not a disaccharide or oligosaccharide moiety, and, where the anionic-containing moiety is a neuraminic- or sialic acid-containing moiety, it is modified in the 4-position by substitution with an amino, amido, cyano, azido or guanido group, or is unsaturated.
为了抑制、预防或治疗患者体内的细菌、酵母菌、真菌或寄生虫,需要向患者注射有效量的树状分子,该树状分子具有多个末端基团,其中至少一个基团与其共价键合或连接成阳离子或阴离子基团。阴离子含有的基团不是二糖或寡糖基团,当阴离子含有的基团是神经酰胺酸或唾液酸含有的基团时,在4位被氨基、酰胺、氰基、叠氮基或鸟氨酸基团取代或不饱和。